Physicians' Academy for Cardiovascular Education

TAVR vs surgery in aortic stenosis: reason for a paradigm flip?

3' education - Mar. 19, 2019 - New Orleans, LA, USA - Janet Wyman

Highly purified omega-3 fatty acid not only lowers first ischemic events, but also recurrent events

3' education - Mar. 19, 2019 - Deepak L. Bhatt, MD

Benefits of early initiation of ARNI in acute HF confirmed in open-label extension study

3' education - Mar. 19, 2019 - Adam DeVore, MD

Cholesterol synthesis inhibitor has potential to be add-on therapy to statin in patients with high CV risk

3' education - Mar. 19, 2019 - Anne Carol Goldberg, MD

Better outcomes in patients with AF and ACS/PCI with NOAC vs. VKA and when dropping aspirin

3' education - Mar. 17, 2019 - New Orleans, LA, USA - John Alexander, MD

Proof-of-concept study shows 84% true AF in those with irregular puls detected with smartwatch

3' education - Mar. 16, 2019 - New Orleans, LA, USA - Michael Valentine, MD

Lifestyle improvement forms foundation of comprehensive guideline for primary prevention

3' education - Mar. 16, 2019 - New Orleans, LA, USA - Dr. Amit Khera

New overarching recommendations in primary prevention guideline should help implementation of advise

3' education - Mar. 16, 2019 - New Orleans, LA, USA - Donna Arnett, MD

How are the guidelines for progressive CAD guiding us in clinical practice?

5' education - Dec. 13, 2018 - John Kastelein, Ulf Landmesser

Progressive CAD despite low LDL-C, an elusive disease?

5' education - Feb. 13, 2019 - Kausik Ray, Wouter Jukema

New recommendations of the ESC/ESH Guidelines on the management of hypertension

3' education - Feb. 11, 2019 - Prof. Bryan Williams - London, UK

Two choices of drugs that reduce CV risk in T2DM

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD

Get involved in May Measurement Month to increase awareness of elevated blood pressure

3' education - Feb. 6, 2019 - Prof. Neil Poulter - London, UK

What are the key issues and challenges impacting clinical management with novel therapeutics lowering cholesterol?

5' education - Feb. 6, 2019 - Kausik Ray, Gilles Montalescot

Diabetes & CVD: Time for a multifactorial approach

10' education - Dec. 6, 2018 - WCC Dubai, UAE - John E Deanfield, MD London, United Kingdom

Translating outcomes to practice: Focus on GLP-1 RA, which patients will benefit?

10' education - Dec. 6, 2018 - WCC Dubai, UAE - Neil Poulter MD - London, UK

Novel therapeutic diabetes approaches: The cardiovascular benefits beyond glucose control

10' education - Dec. 6, 2018 - WCC Dubai, UAE - Lina Badimon, MD Barcelona, Spain

Aspirin for primary prevention of CV events: yes or no?

3' education - Jan. 30, 2019 - Prof. dr. Freek Verheugt - Amsterdam, The Netherlands

Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits

3' education - Jan. 28, 2019 - Dr. Adie Viljoen, MD

Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM

3' education - Jan. 28, 2019 - Dubai, United Arab Emirates - Prof. Eduard Montanya, MD

Less brain damage with intensive BP-lowering in older hypertensives, but no effect on function

News - Mar. 20, 2019

ACC 2019 The randomized INFINITY trial showed a significant reduction in accrual of subcortical white matter disease in older people receiving more intensive antihypertensive therapy, but mobility and cognitive function were not improved.

Pulmonary artery pressure-guided therapy reduced HHF and was safe in HF patients

News - Mar. 19, 2019

ACC 2019 Post-approval analyses of the CardioMEMS PAS trial showed that adapting therapy based on pulmonary artery pressure is effective in reducing hospitalizations for HF and safe in patients with NYHA class III HF.

Angiography timing does not affect survival after cardiac arrest in NSTEMI patients

News - Mar. 19, 2019

ACC 2019 The COACT trial did not show improved survival at 90 days with immediate vs. delayed coronary angiography in NSTEMI patients with return of spontaneous circulation after out-of-hospital cardiac arrest.

TAVR vs surgery in aortic stenosis: reason for a paradigm flip?

3' education - Mar. 19, 2019 - New Orleans, LA, USA - Janet Wyman
Janet Wyman summarizes the results of the PARTNER 3 trial, comparing TAVR with surgery in patients with aortic stenosis. The results will cause a paradigm flip in treatment of these patients and in communicating the treatment plan with them.

ACC 2019 Janet Wyman summarizes the results of the PARTNER 3 trial, comparing TAVR with surgery in patients with aortic stenosis. The results will cause a paradigm flip in treatment of these patients and in communicating the treatment plan with them.

Highly purified omega-3 fatty acid not only lowers first ischemic events, but also recurrent events

3' education - Mar. 19, 2019 - Deepak L. Bhatt, MD
Icosapent ethyl reduces total ischemic events and first and recurrent events compared to placebo. Prof Bhatt explains the results of the REDUCE-IT trial and what this means for high risk patients.

ACC 2019 Icosapent ethyl reduces total ischemic events and first and recurrent events compared to placebo. Prof Bhatt explains the results of the REDUCE-IT trial and what this means for high risk patients.

Benefits of early initiation of ARNI in acute HF confirmed in open-label extension study

3' education - Mar. 19, 2019 - Adam DeVore, MD
Dr. Adam DeVore discusses the results of an open-label extension study of PIONEER-HF. In this study, the effect of sacubitril/valsartan in acute HF was confirmed, showing greatest benefit when started early during hospitalisation.

ACC 2019 Dr. Adam DeVore discusses the results of an open-label extension study of PIONEER-HF. In this study, the effect of sacubitril/valsartan in acute HF was confirmed, showing greatest benefit when started early during hospitalisation.

Cholesterol synthesis inhibitor has potential to be add-on therapy to statin in patients with high CV risk

3' education - Mar. 19, 2019 - Anne Carol Goldberg, MD
The results of the CLEAR WIsdom trial are summarized by prof Goldberg, with lowering of LDL-c in response to bempedoic acid vs placebo as most important finding.

ACC 2019 The results of the CLEAR WIsdom trial are summarized by prof Goldberg, with lowering of LDL-c in response to bempedoic acid vs placebo as most important finding.

Shorter duration of DAPT as safe and effective as 12 months after drug-eluting stent implantation

News - Mar. 19, 2019

ACC 2019 The STOPDAPT-2 and SMART-CHOICE trials both showed that shorter duration of DAPT was non-inferior to 12 months DAPT for ischemic outcomes with reduced bleeding after drug-eluting stent implantation.

Highly purified omega-3 fatty acid lowers first and recurrent ischemic events in hypertriglyceridemia

News - Mar. 19, 2019

ACC 2019 A total events analysis of REDUCE-IT showed that icosapent ethyl can not only reduce first events by 25%, but also second, third or further events by 32%, 31% and 48%, respectively.

SGLT2 inhibitor treatment is beneficial in T2DM patients with a broad range of ejection fractions

News - Mar. 19, 2019

ACC 2019 An analysis of DECLARE-TIMI 58 showed that dapagliflozin was associated with reduced hospitalization for HF and CV death across a range of EF. Benefit seems largest in HFrEF.

Cholesterol synthesis inhibitor reduces LDL-c in high CV risk patients

News - Mar. 19, 2019

ACC 2019 Results of the CLEAR Wisdom trial showed that bempedoic acid lowered LDL-c in high CV risk patients with elevated LDL-c levels who are on maximally tolerated statin and/or other lipid-modifying therapies.

Oral antibiotics to treat left-sided endocarditis as safe and effective as IV therapy in long-run

News - Mar. 18, 2019

ACC 2019 Long-term data of the POET trial now show that switching to oral antibiotics is safe and effective for up to 3.5 years. Oral treatment may halve the length of the hospital stay.